Sep 11, 2018

Renesas buying US chipmaker IDT for $6.7 billion

Dan Primack, author of Pro Rata

Illustration: Rebecca Zisser/Axios

Japan's Renesas Electronics agreed to buy U.S. chipmaker Integrated Device Technology (NSE: IDTI) for $6.7 billion, or $49 per share.

Why it's a big deal: Because it's an interesting test for U.S. and Chinese antitrust authorities, both of which have become reluctant to approve global semiconductor mergers.

Renesas has said it isn't worried, pointing to a lack of product overlap, but acquirers never express concern on announcement day.

Per Reuters' Makiko Yamazaki:

"Renesas has been keen to get its hands on IDT’s know-how in analog semiconductors for wireless networks and sensors — expertise crucial to develop autonomous driving and connected car technology."

Go deeper: Computer chips are still "Made in the USA"

Go deeper

Rashaan Ayesh
47 mins ago - Politics & Policy

Pelosi, Schumer demand postmaster general reverse USPS cuts ahead of election

Schumer and Pelosi. Photo: Alex Wong/Getty Images

House Speaker Nancy Pelosi (D-Calif.) and Senate Minority Leader Chuck Schumer sent a letter to Postmaster General Louis DeJoy on Thursday calling for the recent Trump appointee to reverse operational changes to the U.S. Postal Service that "threaten the timely delivery of mail" ahead of the 2020 election.

Why it matters: U.S. mail and election infrastructure are facing a test like no other this November, with a record-breaking number of mail-in ballots expected as Americans attempt to vote in the midst of a pandemic.

Go deeper (1 min. read)Arrow
Alison Snyder
1 hour ago - Science

CRISPR co-discoverer on the gene editor's pandemic push

Photo illustration: Aïda Amer/Axios. Photos: Brian Ach/Getty Images for Wired and BSIP/UIG via Getty Images

The coronavirus pandemic is accelerating the development of CRISPR-based tests for detecting disease — and highlighting how gene-editing tools might one day fight pandemics, one of its discoverers, Jennifer Doudna, tells Axios.

Why it matters: Testing shortages and backlogs underscore a need for improved mass testing for COVID-19. Diagnostic tests based on CRISPR — which Doudna and colleagues identified in 2012, ushering in the "CRISPR revolution" in genome editing — are being developed for dengue, Zika and other diseases, but a global pandemic is a proving ground for these tools that hold promise for speed and lower costs.

Go deeper (3 min. read)Arrow
Axios
Updated 1 hour ago - Politics & Policy

Coronavirus dashboard

Illustration: Eniola Odetunde/Axios

  1. Global: Total confirmed cases as of 5 p.m. ET: 18,912,947 — Total deaths: 710,318— Total recoveries — 11,403,473 — Map.
  2. U.S.: Total confirmed cases as of 5 p.m. ET: 4,867,916 — Total deaths: 159,841 — Total recoveries: 1,577,851 — Total tests: 58,920,975 — Map.
  3. Politics: Pelosi rips GOP over stimulus negotiations: "Perhaps you mistook them for somebody who gives a damn" — Ohio Gov. Mike DeWine tests positive.
  4. Public health: Majority of Americans say states reopened too quickly — Fauci says task force will examine aerosolized spread.
  5. Business: The health care sector imploded in Q2 — More farmers are declaring bankruptcy — July's jobs report could be an inflection point for the recovery.
  6. Sports: Where college football's biggest conferences stand on playing.
Go deeper (<1 min. read)Arrow